Globally, Glaucoma is the second leading cause of blindness after cataract. In India, approximately 11 million people have lost their vision due to this incurable disease. Compliance is a major concern in treating Glaucoma as nearly 50% of patients admit non-continuous use of medications by 6 months after start of therapy. Multiple dosing limits patient’s adherence to the treatment and thereby, worsens the condition. Patients feel that the treatment of Glaucoma is inconvenient and interferes with their day-to-day life. Bausch+Lomb’s Travoflo is a convenient once-daily-dosing therapy for Glaucoma, which is aimed at improving patient compliance by reducing the number of interruptions and improving the overall outcome.
Print advertisment created by Point Blank, India for Bausch+Lomb, within the category: Health.
“Say Less, Do More”: Words of Inspiration From the 2017 Clio Sports AwardsRead More
Inside the Agency
How DDB’s Ari Weiss And Keith Reinhard Are Embracing Ad Legend Bill Bernbach’s “Rebel Spirit”Read More
Ward+Robes Designer Gowns Offer Individuality for Hospitalized TeensRead More
Empathy, Observation, Openness: IDEO’s Roshi Givechi on the Narrative of Product DesignRead More